UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 55

Sortiert nach

Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

The New England journal of medicine, 2019-05, Vol.380 (20), p.1929-1940

2019

Volltextzugriff (PDF)

Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer

The New England journal of medicine, 2023-05, Vol.388 (18), p.1657-1667

2023

Volltextzugriff (PDF)

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

The New England journal of medicine, 2016-11, Vol.375 (19), p.1823-1833

2016

Volltextzugriff (PDF)

Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial

The lancet oncology, 2015-05, Vol.16 (5), p.550-560

2015

Volltextzugriff (PDF)

Epigenetic regulation of SMARCB1 By miR-206, -381 and -671-5p is evident in a variety of SMARCB1 immunonegative soft tissue sarcomas, while miR-765 appears specific for epithelioid sarcoma. A miRNA study of 223 soft tissue sarcomas

Genes chromosomes & cancer, 2016-10, Vol.55 (10), p.786-802

2016

Volltextzugriff (PDF)

Sounds can boost the awareness of visual events through attention without cross-modal integration

Scientific reports, 2017-01, Vol.7 (1), p.41684-41684, Article 41684

2017

Volltextzugriff (PDF)

Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2020-04, Vol.323 (13), p.1266

2020

Volltextzugriff (PDF)

Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial

BMC cancer, 2018-05, Vol.18 (1), p.598-598, Article 598

2018

Volltextzugriff (PDF)

Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial

Journal of clinical oncology, 2015-07, Vol.33 (20), p.2279-2287

2015

Volltextzugriff (PDF)

First Line Sorafenib Treatment for Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis

Experimental and clinical endocrinology & diabetes, 2019-04, Vol.127 (4), p.240

2019

Volltextzugriff (PDF)

EGFR Protein Expression of KRAS Wild-Type Colorectal Cancer: Predictive Value of the Sidedness for Efficacy of Anti-EGFR Therapy

Pathology oncology research, 2020-07, Vol.26 (3), p.1429-1434

2020

Volltextzugriff (PDF)

Release of circulating tumor cells and cell-free nucleic acids is an infrequent event in synovial sarcoma: liquid biopsy analysis of 15 patients diagnosed with synovial sarcoma

Diagnostic pathology, 2018-10, Vol.13 (1), p.81-81, Article 81

2018

Volltextzugriff (PDF)

A single-center, open-label study investigating the excretion balance, pharmacokinetics, metabolism, and absolute bioavailability of a single oral dose of [14C]-labeled idasanutlin and an intravenous tracer dose of [13C]-labeled idasanutlin in a single cohort of patients with solid tumors

Cancer chemotherapy and pharmacology, 2019-07, Vol.84 (1), p.93-103

2019

Volltextzugriff (PDF)

Primary cardiac angiosarcoma: A case report

Echocardiography (Mount Kisco, N.Y.), 2018-02, Vol.35 (2), p.267-271

2018

Volltextzugriff (PDF)

A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma

Pediatric blood & cancer, 2016-10, Vol.63 (10), p.1761-1770

2016

Volltextzugriff (PDF)

Investigating the Geographic Disparities of Amenable Mortality and Related Ambulance Services in Hungary

International journal of environmental research and public health, 2021-01, Vol.18 (3), p.1065

2021

Volltextzugriff (PDF)

An open‐label, dose‐ranging study of Rolontis, a novel long‐acting myeloid growth factor, in breast cancer

Cancer medicine (Malden, MA), 2018-05, Vol.7 (5), p.1660-1669

2018

Volltextzugriff (PDF)

Exposure to indoor air pollution and the cognitive functioning of elderly rural women: a cross-sectional study using LASI data, India

BMC public health, 2022-12, Vol.22 (1), p.2272-2272, Article 2272

2022

Volltextzugriff (PDF)

Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Phase III Trial

Journal of clinical oncology, 2012-06, Vol.30 (17), p.2070-2078

2012

Volltextzugriff (PDF)

Rare hereditary tumours

Magyar onkologia, 2014-06, Vol.58 (2), p.94

2014

Volltextzugriff (PDF)

Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)

Journal of clinical oncology, 2009-07, Vol.27 (19), p.3126-3132

2009

Volltextzugriff (PDF)

1 – 25 von 55

Suche als RSS-Feed

Aktive Filter

ThemaAdult

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(54)
Mit Volltextzugriff
(44)

Publikationsform

Artikel
(55)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(55)
Female
(51)
Science & Technology
(47)
Life Sciences & Biomedicine
(46)
Middle Aged
(46)
Aged
(42)
Male
(42)
Oncology
(33)
Aged, 80 And Over
(25)
Treatment Outcome
(22)
Tumors
(19)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(16)
Adolescent
(13)
Survival Analysis
(13)
Young Adult
(13)
Chemotherapy
(12)
Disease-Free Survival
(12)
Metastasis
(12)
Biological And Medical Sciences
(11)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial

Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial

Epigenetic regulation of SMARCB1 By miR-206, -381 and -671-5p is evident in a variety of SMARCB1 immunonegative soft tissue sarcomas, while miR-765 appears specific for epithelioid sarcoma. A miRNA study of 223 soft tissue sarcomas

Sounds can boost the awareness of visual events through attention without cross-modal integration

Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial

Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial

Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial

Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial

First Line Sorafenib Treatment for Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis

EGFR Protein Expression of KRAS Wild-Type Colorectal Cancer: Predictive Value of the Sidedness for Efficacy of Anti-EGFR Therapy

Release of circulating tumor cells and cell-free nucleic acids is an infrequent event in synovial sarcoma: liquid biopsy analysis of 15 patients diagnosed with synovial sarcoma

A single-center, open-label study investigating the excretion balance, pharmacokinetics, metabolism, and absolute bioavailability of a single oral dose of [14C]-labeled idasanutlin and an intravenous tracer dose of [13C]-labeled idasanutlin in a single cohort of patients with solid tumors

Primary cardiac angiosarcoma: A case report

A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma

Investigating the Geographic Disparities of Amenable Mortality and Related Ambulance Services in Hungary

An open‐label, dose‐ranging study of Rolontis, a novel long‐acting myeloid growth factor, in breast cancer

Exposure to indoor air pollution and the cognitive functioning of elderly rural women: a cross-sectional study using LASI data, India

Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Phase III Trial

Rare hereditary tumours

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)

Aktive Filter

Suchergebnisse filtern